Silence Therapeutics’ Zerlasiran Shows Promising Results
Company Announcements

Silence Therapeutics’ Zerlasiran Shows Promising Results

Silence Therapeutics (SLN) has released an update.

Silence Therapeutics reports a breakthrough as its phase 2 study of zerlasiran shows substantial and sustained reductions in Lp(a), a key cardiovascular disease risk factor, paving the way for phase 3 trials. The medication, which uses siRNA technology to lower Lp(a) levels, was well received by patients and demonstrated a median reduction of approximately 90% without serious safety concerns. This development offers hope for addressing a significant unmet medical need in cardiovascular health.

For further insights into SLN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlySilence Therapeutics files automatic ordinary shares offering
TheFlyAstraZeneca deal has positive read for Silence Therapeutics, says Morgan Stanley
TheFlyAstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App